Macular Amyloidosis. Amyloidosis of skin (E85.-†)
Conditions
Interventions
Intervention group: Patients diagnosed with macular amyloidosis by a dermatologist and fulfilling the study’s inclusion criteria were enrolled.
Sponsors
Shahed University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of macular amyloidosis by a dermatologist. Normal results for CBC, TSH, BUN, and Creatinine tests.
Exclusion criteria
Exclusion criteria: Having autoimmune diseases Presence of immunodeficiency disorders, including HIV infection Pregnancy Breastfeeding Hypothyroidism Elevated liver enzymes Elevated creatinine levels
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prp treatment. Timepoint: From the beginning of the injection procedure to the fifth month(follow-up). Method of measurement: Recording was performed based on the number of injection sessions according to the patients medical record.;Severity of skin Lesions. Timepoint: All treatment sesions. Method of measurement: Clinical assessment was conducted using the Visual Analogue Scale(VAS) and visual inspection of photo graphs at each treatment session.;History of skin disease. Timepoint: prior to study enrollment. Method of measurement: Patient interviews or review of medical records prior to study enrollment.;Gender. Timepoint: Before enrollment. Method of measurement: Demographic form completed before the start of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction regarding the treatment. Timepoint: post treatment. Method of measurement: A five-point questionnaire was conducted three months post-treatment.;Possible complications. Timepoint: each session. Method of measurement: Clinical evaluation was performed at each session, and patient complaints were recorded. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZohreh Khodashenas
Shahed University
Outcome results
None listed